You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeted Polymer Micelles for Treatment of Metastatic Melanoma

    SBC: INTEZYNE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  2. The anti-tumorigenic and anti-metastatic potential of Eya phosphatase inhibitors

    SBC: SIXONE SOLUTIONS, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Breast cancer is expected to cause 39,510 deaths of American women in 2012 and 450,000 deaths globally. Once breast cancer has spread, it is essentially incurable. A critical barrier to treating advanced breast cancer is the lack of cancer-specific drugs that are effective in a large percentage of cancer patients and have low toxicity. Sixone Solutions, LLC pro ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Live-Cell Fluorescence Lifetime FRET Assays for HTS

    SBC: Fluorescence Innovations, Inc.            Topic: NIDA

    DESCRIPTION (provided by applicant): This project will establish proof-of-concept for a powerful and versatile implementation of live-cell assays in a true high-throughput screening (HTS) format for small-molecule drug discovery. The technological basis isfluorescence lifetime (FLT) readout of FRET between fluorescent fusion proteins. Lifetime measurement is needed in HTS to overcome the low preci ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Early Warning system for detecting pre-eclampsia

    SBC: CONVERGENT ENGINEERING, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Remote focusing through spatial light modulation for multifocal multiphoton micro

    SBC: BOULDER NONLINEAR SYSTEMS, INC.            Topic: NIMH

    DESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Neurorestorative therapy of stroke with HUCBC in T2DM rats

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: NINDS

    DESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Body Worn EMG Controlling of Assistive Robotic Arm for Stroke Rehabilitation

    SBC: ADVANCED MEDICAL ELECTRONICS CORP            Topic: NINDS

    DESCRIPTION (provided by applicant): Stroke is the leading cause of adult disability and the third leading cause of death in the United States. Approximately 15 million people in the world, and more than 700,000 people in the United States, experience a stroke each year. Following a hemispheric stroke, motor control of extremities on one side of the body is usually affected. Many patients suffer a ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model

    SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION            Topic: N

    DESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Oxygen Production and Delivery on Demand

    SBC: GLOBAL RESEARCH & DEVELOPMENT INC            Topic: DHA17B005

    This proposal is in response to the Defense Health Agency 2017 Phase I SBIR topic 17B-005.The approach is the use of a membrane oxygen pump using newly developed nano-thickness membranes with all the layers less than 1 micron total.Nanometer thickness membranes enable more oxygen output per surface area at temperatures of 300-600 C than current state-of-the -art 600-800 C membranes that are 50-300 ...

    STTR Phase I 2018 Department of DefenseDefense Health Agency
  10. A universal eye drop adherence monitor to measure and improve adherence to ocular medications

    SBC: Universal Adherence LLC            Topic: N

    Project Summary Abstract Universal Adherence is an emerging medical device company dedicated to improving adherence to ocular medications through innovative technical solutionsOur proposed Devers Drop DeviceDwill accurately track when a patient removes an eye drop bottle capcommunicate usage data wirelessly to a database that researchers can accessand send alerts to patients when a medication is d ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government